Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
In development
Guidance, NICE advice and quality standards
In development
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter
Skip to results
Filter by title or keyword
Filter
Expected publication date
Expected publication date
From date
To date
Apply date filters
Area of interest
Area of interest
COVID-19 (7)
Type
Type
Guidance (402)
NICE advice (1)
Quality standard (10)
Guidance programme
Guidance programme
Clinical guidelines (28)
Diagnostics guidance (10)
Health technology evaluations (14)
Highly specialised technologies guidance (9)
Interventional procedures guidance (12)
Medical technologies guidance (11)
NICE guidelines (31)
Public health guidelines (1)
Technology appraisal guidance (323)
Advice programme
Advice programme
Medtech innovation briefings (1)
Apply filters
Showing 51 to 100 of 413
Sort by
Title
Date
Apply sorting
Guidance, NICE advice and quality standards in development
Title
Type
Expected publication date
Benralizumab with corticosteroids for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis ID6266
Technology appraisal guidance
TBC
Bevacizumab gamma for treating wet age-related macular degeneration [ID6320]
Technology appraisal guidance
11 December 2024
Bevacizumab in combination with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer [ID1145]
Technology appraisal guidance
20 February 2019
Bimatoprost implant for treating open angle glaucoma or ocular hypertension in people who are unsuitable for topical treatments [ID6180]
Technology appraisal guidance
TBC
Bimekizumab for treating moderate to severe hidradenitis suppurativa [ID6134]
Technology appraisal guidance
20 November 2024
Bipolar disorder: assessment and management (extraordinary review)
NICE guideline
TBC
Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia with no measurable residual disease [ID6405]
Technology appraisal guidance
26 March 2025
Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia with no measurable residual disease ID6405
Health technology evaluation
TBC
Botulinum toxin type A for treating upper or lower limb focal spasticity associated with stroke [ID768]
Technology appraisal guidance
TBC
Breast cancer guidelines
NICE guideline
TBC
Brentuximab vedotin with doxorubicin, dacarbazine and vinblastine for previously untreated late-stage classical Hodgkin lymphoma (including Review of TA594) [ID6334]
Technology appraisal guidance
TBC
Burosumab for treating FGF23-related hypophosphataemia in tumour-induced osteomalacia [ID3924 ]
Technology appraisal guidance
TBC
Burosumab for treating X-linked hypophosphataemia in adults [ID3822]
Technology appraisal guidance
7 August 2024
Cabotegravir for preventing HIV-1 in adults and young people [ID6255]
Technology appraisal guidance
13 November 2024
Cabozantinib for treating advanced hepatocellular carcinoma after prior therapy [ID1243]
Technology appraisal guidance
24 May 2019
Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]
Technology appraisal guidance
TBC
Canakinumab for adjuvant treatment of resectable or resected stage 2A to 3B non-small-cell lung cancer [ID5114]
Technology appraisal guidance
TBC
Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment [ID6370]
Technology appraisal guidance
5 March 2025
Capivasertib with paclitaxel for untreated metastatic triple-negative breast cancer [ID6383]
Technology appraisal guidance
TBC
Cardiometabolic disease prevention and treatment guidelines
NICE guideline
TBC
Cardiovascular risk assessment and lipid modification
Quality standard
23 July 2025
Cediranib with olaparib for treating recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer after 3 therapies [ID1639]
Technology appraisal guidance
TBC
Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer [ID3949]
Technology appraisal guidance
30 April 2025
Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (review of HST12) [ID6145]
Highly specialised technology
13 November 2024
Chronic heart failure in adults: diagnosis and management - Pharmacological treatment of chronic heart failure
NICE guideline
TBC
Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies [ID4012]
Technology appraisal guidance
TBC
Cimavax for treating wild-type EGFR-positive non-small-cell lung cancer [1259]
Technology appraisal guidance
TBC
Cladribine for treating relapsing multiple sclerosis ID6263
Technology appraisal guidance
5 February 2025
Cobolimab with dostarlimab and docetaxel for treating advanced non-small-cell lung cancer after anti-PD-L1 treatment and chemotherapy [ID6398]
Technology appraisal guidance
TBC
COLOFIT algorithm to guide colorectal cancer pathway referral in primary care: early value assessment
Health technology evaluation
TBC
Colon cancer (adjuvant) - irinotecan [ID379]
Technology appraisal guidance
TBC
Compression products for wound care: late stage assessment
Health technology evaluation
29 April 2025
Cositecan for treating platinum or taxane resistant advanced, mucinous, epithelial ovarian cancer [ID826]
Technology appraisal guidance
TBC
Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer (MA review of TA529) [ID6289]
Technology appraisal guidance
16 October 2024
Crovalimab for treating paroxysmal nocturnal haemoglobinuria [ID6140]
Technology appraisal guidance
30 October 2024
CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attack
Diagnostics guidance
31 July 2024
Danicopan as an add-on treatment to a C5 inhibitor for treating extravascular haemolysis in adults with paroxysmal nocturnal haemoglobinuria [ID5088]
Technology appraisal guidance
11 September 2024
Dapagliflozin for treating chronic kidney disease [ID6411]
Technology appraisal guidance
12 February 2025
Daprodustat for treating anaemia in people with chronic kidney disease [ID3987]
Technology appraisal guidance
TBC
Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when high-dose chemotherapy with stem cell transplant is unsuitable [ID3843]
Technology appraisal guidance
TBC
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297
Technology appraisal guidance
28 July 2021
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297
Technology appraisal guidance
TBC
Datopotamab deruxtecan for previously treated hormone receptor-positive HER2-negative unresectable or metastatic breast cancer [ID6348]
Technology appraisal guidance
TBC
Datopotamab deruxtecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy [ID6241]
Technology appraisal guidance
TBC
DCVax-L for treating glioblastoma [ID836]
Technology appraisal guidance
TBC
Degarelix before or with radiotherapy for treating high-risk localised and locally advanced hormone-dependent prostate cancer [ID6419]
Technology appraisal guidance
TBC
Delandistrogene moxeparvovec for treating Duchenne muscular dystrophy in children 4 to 7 years ID 3897
Technology appraisal guidance
TBC
Delgocitinib for treating moderate to severe chronic hand eczema ID6408
Technology appraisal guidance
TBC
Diabetic retinopathy
NICE guideline
13 August 2024
Diabetic retinopathy - ruboxistaurin [ID382]
Technology appraisal guidance
TBC
Previous page
1
Current page
2
3
4
…
9
Page
2
of
9
Next page
Results per page
10
25
50
All
Back to top